- By ICR Secretariat
- Posted Monday, January 30, 2023
Ipsen's Onivyde proves its worth in aggressive pancreatic cancer
https://www.fiercepharma.com/pharma/ipsens-onivyde-proves-its-worth-previously-untreated-specific-pancreatic-cancer
Ipsen, which is “not at all afraid" to challenge Big Pharma, according to CEO David Loew, is touting a win for its oncology pipeline.
The oldest independent membership-led professional body for clinical researchers across the globe.
Latest Posts
- ICR Spring Ethics & GCP Forum (1) 07/02/2023 10:26 AM
- Trial blazing 07/02/2023 09:47 AM
- AstraZeneca targets the 9 out of 10 people who don't know they have CKD in new TV spot 07/02/2023 09:45 AM
Useful Links
Contact Us
Suite 11a, Cedar Court
Grove Park
White Waltham
Maidenhead
SL6 3LW
info@icr-global.org